CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

Inclusion Criteria:

* Patients age ≥18 years old
* Histologically confirmed renal cell carcinoma
* Adequate organ function including:
* \- Platelet count of \> 50,000/mm3
* \- Neutrophil count of \> 1000/mm3
* \- Serum Cr \< 1.5 x ULN or estimated GFR \> 60 ml/min based upon Cockroft-Gault equation
* \- Proteinuria \< 1 g/24 hours based upon 24 hour urine collection or spot urine protein/creatinine ratio
* \- AST and ALT \< 2.5 x ULN (\< 5 x ULN in patients with known liver metastases)
* \- Total bilirubin \< 1.5 x ULN (\< 3 x ULN in patients with known/suspected Gilbert's disease)
* ECOG performance status of 0 or 1
* Able to provide written informed consent and willing to comply with protocol requirements
* No contra-indication to MR including severe claustrophobia, incompatible aneurysm clips or cardiac pacemaker
* For participants of childbearing potential, not pregnant, and use of effective contraceptive methods during the trial and within 6 months following radiotracer injection
* Cohort A only: Presence of at least three distinct metastatic lesions by standard imaging including whole body bone scan + cross-sectional imaging of the abdomen and pelvis obtained within 12 weeks prior to protocol scan
* Cohort B only: (N = 5 evaluable patients): Planned nephrectomy within 12 weeks following protocol scan

Exclusion Criteria:

* Patients with or with a history of uncontrolled bleeding diathesis
* Inadequate venous access per assessment of treating health care provider
* Receipt of radioisotope within 5 physical half-lives prior to trial enrollment
* Prior treatment with alpha radiation therapy (Radium Ra 223 chloride; Xofigo™) during the previous 60 days
* Have a medical condition or other circumstances that, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the trial.
* Prior history of any other malignancy within past three years, except melanomatous skin cancer or carcinoma in situ.